Related Experiment Videos
A hepatologist's view of variceal bleeding
1Department of Medicine, Tufts University School of Medicine, Faulkner Hospital, Boston, Massachusetts 02130.
American Journal of Surgery
|July 1, 1990
Summary
Esophagogastric varices pose significant bleeding risks in cirrhosis patients. Nonselective beta-blockers show promise for preventing initial variceal bleeding, while sclerotherapy or beta-blockers manage recurrent bleeding based on liver function.
Area of Science:
- Gastroenterology
- Hepatology
- Clinical Medicine
Background:
- Cirrhosis patients with esophagogastric varices face high risks of initial (25-33%) and recurrent (up to 70%) bleeding.
- Variceal bleeding carries a substantial mortality risk, up to 50%.
Purpose of the Study:
- To review and recommend evidence-based strategies for managing acute variceal bleeding.
- To identify optimal methods for preventing recurrent variceal hemorrhage.
- To evaluate the efficacy of different therapeutic interventions.
Main Methods:
- Review of prospective randomized trials.
- Analysis of treatment protocols for acute variceal bleeding control.
- Assessment of preventative measures for recurrent variceal hemorrhage.
Main Results:
- Acute bleeding management: Vasopressin plus nitroglycerin for minor episodes, sclerotherapy for severe, and esophageal staple transection for refractory cases.
- Recurrent bleeding prevention: Nonselective beta-adrenergic blockers (propranolol, nadolol) for Child's A/B cirrhosis; sclerotherapy for Child's C.
- Emergency portasystemic shunt surgery is not currently recommended.
Conclusions:
- Nonselective beta-adrenergic blockers are promising for preventing initial variceal bleeding.
- Treatment strategies for variceal bleeding and hemorrhage prevention should be tailored to disease severity and liver function.
- Medical management should be prioritized over surgical interventions for bleeding control.